Register
EU Committee Backs Delafloxacin for ABSSSI |
Clinical News
eMediNexus Coverage from: 
EU Committee Backs Delafloxacin for ABSSSI
eMediNexus,  21 October 2019
remove_red_eye 511 Views
#Business And Medicine #Infectious Diseases #Pharmacist

1 Read Comments                

The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) recommended delafloxacin (Quofenix, A. Menarini Industrie Farmaceutiche Riunite) for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSI) when other antibacterial agents commonly used for the initial treatment of such infections are considered inappropriate.

Practitioners should consult official guidance regarding the "appropriate use of antibacterial agents," the EMA said in an opinion summary… (Medscape)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now